- cafead May 24, 2024 at 11:32: AM
via At Tuesday’s Investor Day 2024 event, AstraZeneca laid out an ambitious plan to reach $80 billion in total revenue by 2030—up from $45.8 billion in 2023—and to launch 20 new medicines by the end of the decade. CEO Pascal Soriot declared it’s a “new era of growth” for the U.K.-based company that he contends will be achieved through its existing portfolio, as well as 20 new therapies, “many with the potential to generate more than $5 billion in peak year revenues.”
Why should we believe AstraZeneca can meet this lofty goal of nearly doubling sales? In a presentation to investors on Tuesday, Soriot said the company has a track record of success—specifically, by delivering last year on its ambitious $45 billion revenue goal set a decade ago, up from $22.1 billion in 2018.
article source
Why should we believe AstraZeneca can meet this lofty goal of nearly doubling sales? In a presentation to investors on Tuesday, Soriot said the company has a track record of success—specifically, by delivering last year on its ambitious $45 billion revenue goal set a decade ago, up from $22.1 billion in 2018.
article source